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Several high-risk HLA allele mismatch combinations (HR-MMs) for severe acute graft-versus-host disease
(GVHD) have been identiﬁed by analyzing transplantation outcomes in Japanese unrelated hematopoietic
stem cell transplant recipients. In this study, we analyzed the effects of HR-MMs in 3 transplantation time
periods. We conﬁrmed that the incidence of grade III to IV acute GVHD in the HR-MM group was signiﬁcantly
higher than that in the low-risk (LR) MM group (hazard ratio [HR], 2.74; P < .0001) in the early time period
(1993 to 2001). However, the difference in the incidence of grade III to IV acute GVHD between the HR-MM
and LR-MM groups was not statistically signiﬁcant (HR, 1.06; P ¼ .85 and HR, .40; P ¼ .21, respectively) in the
mid (2002 to 2007) and late (2008 to 2011) time periods. Similarly, survival in the HR-MM group was
signiﬁcantly inferior to that in the LR-MM group (HR, 1.46; P ¼ .019) in the early time period, whereas the
difference in survival between the 2 groups was not statistically signiﬁcant in the mid and late time periods
(HR, 1.06; P ¼ .75 and HR, .82; P ¼ .58, respectively). In conclusion, the adverse impact of HR-MM has become
less signiﬁcant over time. Unrelated transplantation with a single HR-MM could be a viable option in the
absence of a matched unrelated donor or an unrelated donor with a single LR-MM.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) from an
unrelated donor has been established as an effective treat-
ment option for patients with hematological diseases who
lack a human leukocyte antigen (HLA)ematched relatededgments on page 535.
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14.01.003donor. However, an HLA mismatch at the genetic level (allele
mismatch) may be observed even in HSCT from a serologi-
cally HLA-matched donor (antigen match), and the presence
of an allele mismatch adversely affects the incidence of
severe acute graft-versus-host disease (GVHD) and survival
[1-4]. We recently showed that the presence of single HLA
allele mismatches at the HLA-A, -B, -C, or -DRB1 loci equiv-
alently affect the outcome of HSCT, although a previous study
from Japan reported that an HLA-A or -B allele mismatch
impairs overall survival more strongly than an HLA-C or
-DRB1 allele mismatch [4,5]. These ﬁndings suggest that theTransplantation.
Table 1
Patient Characteristics
Characteristic Match n ¼ 2504 Low-Risk Mismatch n ¼ 1057 High-Risk Mismatch n ¼ 157
Early Mid Late Early Mid Late Early Mid Late
802 814 888 412 351 294 64 71 22
Age (recipient)
Median 32 38 43 31 38 43 33 39 41
Age (donor)
Median 34 34 36 33 34 37 35 36 37
Sex (recipient)
Female 292 305 378 162 165 123 27 27 9
Male 510 509 510 250 186 171 37 44 13
Sex (donor)
Female 286 262 266 164 158 107 20 28 5
Male 512 548 622 247 190 187 43 43 17
N.A. 4 4 0 1 3 0 1 0 0
Sex mismatch
Match 507 537 512 238 209 166 35 40 14
Male to female 148 158 244 85 72 72 17 15 6
Female to male 143 115 132 88 67 56 11 16 2
N.A. 4 4 0 1 3 0 1 0 0
ABO blood type
Match 454 462 500 167 151 121 33 31 9
Minor mismatch 154 162 175 112 84 81 15 18 3
Major mismatch 125 114 142 82 67 61 9 18 4
Bidirectional mismatch 58 70 71 45 46 31 7 4 6
N.A. 11 6 0 6 3 0 0 0 0
Disease
AML 269 415 495 134 168 170 15 29 12
ALL 229 229 249 116 96 76 11 23 8
CML 237 84 29 125 42 14 30 3 0
MDS 67 86 115 37 45 34 8 16 2
Disease risk
Low 552 533 607 265 219 181 40 38 12
High 230 239 280 135 116 113 21 28 10
Others 20 42 1 12 16 0 3 5 0
Cell dose (cells/kg)
Median 3.0 2.7 2.7 3.0 2.6 2.6 3.1 2.8 2.6
GVHD prophylaxis
CSA-based 545 306 185 267 114 47 45 21 2
TAC-based 240 499 689 135 227 240 19 50 20
N.A. 17 9 14 10 10 7 0 0 0
Conditioning regimen
TBI regimen 760 639 560 394 272 194 59 53 15
Non-TBI regimen 30 114 328 17 52 100 3 11 7
N.A. 12 61 0 1 27 0 2 7 0
N.A. indicates not available; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; GVHD, graft-versus-host disease; CSA, cyclosporine; TAC, tacrolimus; TBI, total body irradiation.
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time periods.
Some investigators have tried to identify speciﬁc donor-
recipient allele combinations that may be associated with a
higher risk of severe acute GVHD [6,7]. Kawase et al. found
16 high-risk HLA allele mismatch combinations (HR-MMs)
for severe acute GVHD [7]. They also showed that the
number of HR-MMs was associated with severe GVHD and
poor survival, whereas the presence of mismatch combi-
nations other than HR-MMs (low-risk mismatch combi-
nations, LR-MMs) did not affect the outcome of HSCT.
However, their study included a variety of benign and
malignant hematological diseases. In addition, they
included donor-recipient pairs with more than 1 HLA
mismatch. The impact of each speciﬁc mismatch combi-
nation was evaluated after adjusting for the number of HLA
mismatches in other loci in a multivariate model, but the
possible presence of HR-MMs in other loci or the interac-
tion between HLA mismatch combinations could not be
appropriately treated in their model. At that time, the
study design was inevitable, because the number of eachHLA mismatch combination was limited. However, several
years have passed and the amount of unrelated HSCT data
in the Transplant Registry Uniﬁed Management Program
(TRUMP) has increased to more than 13,500 donor-
recipient pairs. Therefore, in this study, we reanalyzed
the impact of HR-MMs, excluding HSCT with multiple HLA
mismatches in patients with relatively homogeneous
background diseases. In addition, we evaluated the impact
of HLA mismatch on transplantation outcomes considering
the period effect, because the impact of HR-MM mismatch
might have changed over time periods, as we previously
reported in an analysis of single HLA allele mismatches at
the HLA-A, -B, -C, and -DRB1 loci [5].METHODS
Patients
Patients aged at least 16 years with acute myeloblastic leukemia, acute
lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloge-
nous leukemia (CML) who underwent a ﬁrst HSCT from a serologically HLA-
A, -B, and -DR matched unrelated donors between 1993 and 2011, and who
had full HLA-A, -B, -C, and -DRB1 allele data, were included in this study.
Bone marrow was exclusively used as a stem cell source. Clinical data for
Table 2
Multivariate Analysis to Evaluate the Impact of Single HLA Allele Mismatches on the Incidence of Grade III to IV Acute GVHD Stratiﬁed according to the
Transplantation Time Period
Year Factor Hazard Ratio P Value
1993-2001
Donor age 1.02 (1.00-1.03) .082
Donor sex Female 1.00
Male 1.65 (1.05-2.60) .031
Female to male transplantation No 1.00
Yes 1.52 (.91-2.55) .11
Disease AML 1.00
ALL 1.15 (.79-1.68) .47
CML 1.62 (1.11-2.36) .012
MDS .65 (.32-1.35) .25
Disease risk Low 1.00
High 1.30 (.93-1.83) .13
Others .80 (.23-2.85) .74
GVHD prophylaxis CSA-based 1.00
TAC-based .83 (.61-1.14) .25
HLA Low-risk mismatch 1.00
Match .89 (.65-1.21) .44
High-risk mismatch 2.74 (1.73-4.32) <.0001
2002-2007
Donor age 1.03 (1.01-1.05) .0028
Donor sex Female 1.00
Male 1.50 (.96-2.33) .076
Female to male transplantation No 1.00
Yes 1.53 (.89-2.64) .13
Disease AML 1.00
ALL 1.36 (.95-1.96) .094
CML 1.27 (.74-2.20) .38
MDS 1.25 (.77-2.02) .37
Disease risk Low 1.00
High 1.76 (1.25-2.48) .0011
Others 1.65 (.82-3.34) .16
GVHD prophylaxis CSA-based 1.00
TAC-based .86 (.63-1.19) .37
HLA Low-risk mismatch 1.00
Match .64 (.46-.89) .008
High-risk mismatch 1.06 (.58-1.93) .85
2008-2011
Donor age 1.03 (1.01-1.06) .0016
Donor sex Female 1.00
Male 1.28 (.78-2.12) .33
Female to male transplantation No 1.00
Yes .98 (.52-1.88) .96
Disease AML 1.00
ALL 1.18 (.80-1.74) .42
CML 1.53 (.69-3.37) .3
MDS .66 (.36-1.20) .17
Disease risk Low 1.00
High 1.53 (1.08-2.17) .018
Others NA (NA-NA) NA
GVHD prophylaxis CSA-based 1.00
TAC-based .82 (.55-1.24) .34
HLA Low-risk mismatch 1.00
Match .56 (.39-.80) .0014
High-risk mismatch .40 (.10-1.64) .21
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; GVHD,
graft-versus-host disease; CSA, cyclosporine; TAC, tacrolimus.
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who lacked data on survival status, those with more than 1 allele or antigen
mismatch, those who received a reduced-intensity conditioning regimen,
and those who received ex vivo or in vivo T cell depletion, such as antithy-
mocyte globulin or alemtuzumab. Finally, 3718 patients were included in the
main part of this study. As a post hoc analysis, 415 patients with 2 LR-MMs
and 66 patients with 2 allele mismatches including at least 1 HR-MM were
added to compare the impact of 1 HR-MM and 2 LR-MMs and to analyze the
statistical interaction between HR-MM and the presence of an additional
allele mismatch. The study was approved by the data management com-
mittee of TRUMP and by the institutional review board of Saitama Medical
Center, Jichi Medical University.
Histocompatibility
Histocompatibility data for serological and genetic typing for the HLA-A,
HLA-B, HLA-C, and HLA-DR loci were obtained from the TRUMP database,which includes HLA allele data determined retrospectively by the Japan
Marrow Donor Program using frozen samples [7,9]. In this study, the
following donor-recipient HLA-mismatch combinations were regarded
as HR-MMs: A*02:06-A*02:01, A*02:06-A*02:07, A*26:02-A*26:01,
A*26:03-A*26:01, B*15:01-B*15:07, C*03:03-C*15:02, C*03:04-C*08:01,
C*04:01-C*03:03, C*08:01-C*03:03, C*14:02-C*03:04, C*15:02-C*03:04,
C*15:02-C*14:02, DR*04:05-DR*04:03, and DR*14:03-DR*-DR1401, as we
did not have enough data on HLA-DP and -DQ [7]. In HR-MM pairs, the
donor and the recipient must have the HLA allele as shown above, and at the
same time, these donor and recipient HLA alleles should not be shared by
the recipient and the donor, respectively. For example, if the donor has HLA-
A*02:06/02:06 and the recipient has HLA-A*02:01/02:06, this pair was not
regarded as HR-MM pair, as the donor’s HLA-A*02:06 was shared by the
recipient. Other HLA mismatch pairs were regarded as LR-MM pairs. Only
the HLA-C mismatch group included HLA mismatch at a serological (anti-
gen) level.
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Figure 1. The cumulative incidence of grade III to IV acute GVHD grouped according to the HLA mismatch between the donor and recipient in the early (A), mid (B),
and late time periods (C). HR-MM indicates high-risk mismatch; LR-MM, low-risk mismatch; MUD, matched unrelated donor.
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We divided the patients into 3 groups according to the time period
when HSCT was performed to evaluate whether the impact of HR-MM
changed over time periods: the early, mid, and late groups included
HSCT performed from 1993 through 2001, 2002 through 2007, and 2008
through 2011, respectively. The break points among groups were deter-
mined to make the number of patients in each group equivalent (n ¼ 1278,
1236, and 1204, respectively). To avoid making misleading conclusions by
arbitrary grouping, we conﬁrmed that there was a statistically signiﬁcant
interaction between the presence of HR-MMs and transplantation year as a
continuous variable, both for overall survival (P ¼ .0098) and the incidence
of grade III to IV acute GVHD (P < .001). The following analyses were
performed separately in each group. However, in post hoc analyses to
evaluate the impact of HR-MMs at each locus and to compare 1 HR-MM and
2 LR-MMs, the mid and late groups were combined to increase the statis-
tical power, after conﬁrming that similar results were obtained in the 2
groups.The primary endpoint was the incidence of grade III to IV acute GVHD.
Overall survival was evaluated as a secondary endpoint. The chi-square test
or Fisher exact test was used to compare categorical variables and Student
t-test or an analysis of variance test was used for continuous variables to
evaluate the homogeneity of background characteristics of the HR-MM,
LR-MM, and HLA-matched (MUD) groups. P values were adjusted using
the Bonferroni’s method and Tukey’s method for multiple comparisons
between each pair. Overall survival was estimated according to the Kaplan-
Meier method, and compared among groups with the log-rank test. The
incidence of acute GVHD was calculated treating death without GVHD as a
competing event, and it was compared using Gray’s test [10].
The impact of HR-MMs was evaluated using multivariate models: the
Cox proportional hazards model was used for overall survival and Fine and
Gray’s proportional hazards model was used for acute GVHD [11]. The
LR-MM group was regarded as the reference group. Potential confounding
factors that were considered in these analyses included recipient/donor age,
recipient/donor sex, sex mismatch, ABO major/minor mismatch, the use of
Table 3
Multivariate Analysis to Evaluate the Impact of Single High-Risk Allele Mismatches on Overall Survival Stratiﬁed According to the Transplantation Time Period
Year Factor Hazard Ratio P Value
1993-2001
Age 1.02 (1.01-1.03) <.0001
Sex Female 1.00
Male 1.06 (.90-1.23) .51
Disease AML 1.00
ALL 1.20 (.99-1.45) .065
CML .89 (.72-1.10) .29
MDS .61 (.45-.83) .0015
Disease risk Low 1.00
High 2.72 (2.30-3.23) <.0001
Others 2.03 (1.27-3.23) .0029
ABO major mismatch Absent 1.00
Present 1.25 (1.06-1.47) .0092
GVHD prophylaxis CSA-based 1.00
TAC-based .85 (.72-1.00) .049
HLA Low-risk mismatch 1.00
Match .86 (.73-1.01) .063
High-risk mismatch 1.46 (1.06-2.01) .019
2002-2007
Age 1.01 (1.00-1.02) .0025
Sex Female 1.00
Male 1.20 (1.02-1.41) .0027
Disease AML 1.00
ALL 1.16 (.96-1.39) .13
CML .84 (.62-1.12) .23
MDS .56 (.43-.73) <.0001
Disease risk Low 1.00
High 2.87 (2.41-3.40) <.0001
Others 2.23 (1.58-3.15) <.0001
ABO major mismatch Absent 1.00
Present .97 (.81-1.16) .77
GVHD prophylaxis CSA-based 1.00
TAC-based .97 (.83-1.15) .76
HLA Low-risk mismatch 1.00
Match .83 (.69-.98) .032
High-risk mismatch 1.06 (.75-1.48) .75
2008-2011
Age 1.02 (1.01-1.03) <.0001
Sex Female 1.00
Male 1.08 (.89-1.31) .42
Disease AML 1.00
ALL .97 (.76-1.25) .83
CML .97 (.57-1.64) .9
MDS .65 (.48-.87) .004
Disease risk Low 1.00
High 2.73 (2.23-3.35) <.0001
Others NA (NA-NA) NA
ABO major mismatch Absent 1.00
Present 1.14 (.92-1.41) .22
GVHD prophylaxis CSA-based 1.00
TAC-based .95 (.75-1.21) .69
HLA Low-risk mismatch 1.00
Match .86 (.69-1.06) .15
High-risk mismatch .82 (.42-1.62) .58
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; GVHD,
graft-versus-host disease; CSA, cyclosporine; TAC, tacrolimus.
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marrow graft, the use of cyclosporine or tacrolimus as GVHD prophylaxis,
background disease, and disease risk. Acute leukemia in ﬁrst or second
remission, CML in ﬁrst or second chronic phase, CML in accelerated phase,
and myelodysplastic syndrome of refractory anemia or refractory anemia
with excess blasts were considered low-risk diseases, and other conditions
were considered high-risk diseases. All of these potential confounding
factors were included in the multivariate analyses and then deleted in a
stepwise fashion from the model to exclude factors with a P value of .05 or
higher. Finally, HLA mismatch was added to the model. Different multivar-
iate models were compared using the likelihood ratio test. The quantity of
interest was the deviance difference between the 2 models, under the null
hypothesis that 2 models ﬁt the data equally well and the deviance differ-
ence has an approximate chi-square distribution with degrees of freedom
equal to the difference in the number of independent variables between the
compared models.All P values were 2 sided and P values of .05 or less were considered
statistically signiﬁcant. All statistical analyses were performed with EZR
(Saitama Medical Center, Jichi Medical University) [12], which is a graphical
user interface for R (The R Foundation for Statistical Computing). More
precisely, it is a modiﬁed version of R commander that was designed to add
statistical functions frequently used in biostatistics.
RESULTS
Patients
The patient characteristics are summarized in Table 1.
HR-MMs were observed in 64 of 1278, 71 of 1236, and 22 of
1204 donor-recipient pairs in the early, mid, and late time
periods, respectively. On the other hand, 412, 351, and 294
pairs had LR-MMs, respectively. With regard to the
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Figure 2. Overall survival grouped according to the HLA mismatch between the donor and recipient in the early (A), mid (B), and late time periods (C). The survival
curves were adjusted for other signiﬁcant factors by the mean of covariates method, in which average values of covariates are entered into the Cox proportional
hazards model. HR-MM, high-risk mismatch; LR-MM, low-risk mismatch; MUD, matched unrelated donor.
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numbers of LR-MMs and HR-MMs decreased in the late time
periods, ie, after the introduction of routine typing for HLA-C
and the publication of a paper about HR-MMs [7]. The pro-
portion of HSCTs for CML also dramatically decreased over
time periods (30.7%, 10.4%, and 3.6% in the early, mid, and
late periods, respectively). With regard to the difference
among HLA mismatch groups, the proportion of patients
with high-risk underlying disease in the MUD group (29.9%)
was signiﬁcantly lower than those in the HR-MM (37.6%) and
LR-MM groups (34.4%). In addition, the proportion of HSCTs
for CML was signiﬁcantly higher in the HR-MM group in the
early time period (29.6%, 30.3%, and 46.9% in the MUD, LR-
MM, and HR-MM groups, respectively).Incidence of Grade III to IV Acute GVHD
To adjust the impact of HLA mismatch for possible con-
founding factors, we identiﬁed the following independently
signiﬁcant factors for the incidence of grade III to IV acute
GVHD: donor age, donor sex, sex mismatch, disease, disease
risk, and GVHD prophylaxis. After we adjusted for these
factors, we conﬁrmed that the incidence of grade III to IV
acute GVHD in the HR-MM group was signiﬁcantly higher
than that in the LR-MM group (hazard ratio [HR], 2.74; 95%
conﬁdence interval [CI], 1.73 to 4.32; P < .0001) in the early
time period, whereas the difference between the MUD and
LR-MM groups was not signiﬁcant (HR, .89; 95% CI, .65 to
1.21; P ¼ .44) (Table 2, Figure 1). On the other hand, in the
mid and late time periods, the difference in the incidence of
0 500 1000 1500 2000
0.0
0.2
0.4
0.6
0.8
1.0
Days
P
ro
ba
bi
lit
y
30 9 9 8 7
122 80 77 72 69
232 165 153 145 133
HR MM
LR MM
MUD
Number at risk
Donor type
HR MM
LR MM
MUD
Early time period, CML
0 500 1000 1500 2000
0.0
0.2
0.4
0.6
0.8
1.0
Days
P
ro
ba
bi
lit
y
34 18 12 11 8
274 144 119 109 100
542 333 271 235 223
HR MM
LR MM
MUD
Number at risk
Donor type
HR MM
LR MM
MUD
Early time period, Other than CML
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0
Days
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 g
ra
de
 II
I-I
V
 a
cu
te
 G
V
H
D
30 21 16 14 12 12
122 104 90 88 84 82
230 204 186 179 177 172
HR MM
LR MM
MUD
Number at risk
Donor group
HR MM
LR MM
MUD
Early time period, CML
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0
Days
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 g
ra
de
 II
I-I
V
 a
cu
te
 G
V
H
D
31 25 21 19 19 18
276 248 228 212 203 196
549 484 454 435 420 398
HR MM
LR MM
MUD
Number at risk
Donor group
HR MM
LR MM
MUD
Early time period, other than CML
Figure 3. Adjusted overall survival (A,B) and the cumulative incidence of grade III to IV acute GVHD (C,D) grouped according to the underlying disease in the early
time period. CML, chronic myelogenous leukemia; HR-MM, high-risk mismatch; LR-MM, low-risk mismatch; MUD, matched unrelated donor.
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groups was not statistically signiﬁcant (HR, 1.06; 95% CI, .58
to 1.93; P ¼ .85 and HR, .40; 95% CI; .10 to 1.64; P ¼ .21,
respectively). The presence of LR-MM signiﬁcantly adversely
affected the incidence of grade III to IV acute GVHD in the
mid and late periods (HR, .64; 95% CI, .46 to .89; P ¼ .008 and
HR, .56; 95% CI, .39 to .80; P ¼ .0014, respectively, for the
MUD group).
Similarly, the presence of HR-MM signiﬁcantly affected
the incidence of grade II to IV acute GVHD comparedwith LR-
MM only in the early time period (HR, 1.53; 95% CI, 1.05 to
2.24; P ¼ .028), and not in the mid and late periods (HR, .92;
95% CI, .61 to 1.37; P ¼ .67 and HR, .79; 95% CI, .40 to 1.58;
P ¼ .51, respectively).Overall Survival
After adjusting for recipient age, recipient sex, presence of
ABO-major mismatch, disease, disease risk, and GVHD pro-
phylaxis, we again conﬁrmed that survival in the HR-MM
group was signiﬁcantly inferior to that in the LR-MM group
(HR, 1.46; 95% CI, 1.06 to 2.01; P ¼ .019) in the early time
period, whereas there was no signiﬁcant difference between
the MUD and LR-MM groups (HR, .86; 95% CI, .73 to 1.01;
P ¼ .063) (Table 3). On the other hand, the difference in
survival between the HR-MM and LR-MM groups was not
statistically signiﬁcant in the mid and late time periods (HR,
1.06; 95% CI, .75 to 1.48; P ¼ .75 and HR, .82; 95% CI, .42 to
1.62; P ¼ .58, respectively). The difference in survival be-
tween the MUD and LR-MM groups was consistent among
0 20 40 60 80 100
0.0
0.2
0.4
0.6
0.8
1.0
Days
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 g
ra
de
 II
I-I
V
 a
cu
te
 G
V
H
D
25 19 17 13 13 12
50 48 44 42 37 35
16 13 13 13 13 13
632 568 498 457 438 413
1656 1535 1426 1344 1273 1218
AB-HR MM
C-HR MM
DR-HR MM
LR MM
MUD
Number at risk
Donor group
AB-HR MM
C-HR MM
DR-HR MM
LR MM
MUD
Mid-Late time period
0 500 1000 1500 2000
0.0
0.2
0.4
0.6
0.8
1.0
Days
P
ro
ba
bi
lit
y
27 14 10 7 7
50 26 20 16 12
16 9 7 6 5
627 303 205 136 80
1674 880 547 362 241
AB-HR MM
C-HR MM
DR-HR MM
LR MM
MUD
Number at risk
Donor type
AB-HR MM
C-HR MM
DR-HR MM
LR MM
MUD
Mid-Late time period
Figure 4. The cumulative incidence of grade III to IV acute GVHD (A) and adjusted overall survival (B) grouped according to the HLA mismatch loci between the donor
and recipient in the mid or late time period. AB-HR MM, high-risk mismatch at the HLA-A or -B locus; C-HR MM, high-risk mismatch at the HLA-C locus; DR-HR MM,
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period (HR, .83; 95% CI, .69 to .98; P ¼ .032). Figure 2 shows
the overall survival curves grouped according to the HLA-
mismatch groups in each time period, adjusted for other
signiﬁcant factors by the mean of covariates method.Disease-speciﬁc Effects of HR-MM in the Early Period
The number of patients with CMLwas signiﬁcantly higher
in the early period than in the mid and late periods. There-
fore, we evaluated the disease-speciﬁc impact of HR-MM in
the early period. As shown in Figures 3A and B, the presence0 20 40 60 80 100
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mismatches including at least 1 HR-MM.of HR-MM had an adverse impact on overall survival only in
patients with CML, although HR-MM showed a similar
adverse impact on the incidence of grade III to IV acute GVHD
regardless of the underlying disease (Figure 3C, D). Of the 24
CML patients who died after HSCT with HR-MM, 23 died
without relapse of CML, and 10 of these patients died
without grade III to IV acute GVHD.Impact of HR-MM at Each Locus
To evaluate the impact of HR-MM at each locus in the mid
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acute GVHD and survival tended to be similar in these 2 time
periods. The presence of HR-MMs at the HLA-A/B (HLA-A or
-B), HLA-C, and HLA-DRB1 loci was not associated with
signiﬁcantly different survival compared with the LR-MM
group (HR, 1.23; 95% CI, .76 to 1.98; P ¼ .41; HR, .96; 95% CI,
.65 to 1.44; P ¼ .86; and HR, .95; 95% CI, .45 to 2.02; P ¼ .89,
respectively. Figure 4A). However, the incidence of grade III
to IV acute GVHD was higher in patients who had HR-MM at
the HLA-A/B locus than in those with LR-MM, although this
difference was not statistically signiﬁcant (HR, 1.78; 95% CI,
.86 to 3.66; P ¼ .12; HR, .63; 95% CI, .28 to 1.41; P ¼ .26; and
HR, .69; 95% CI, .15 to 3.12; P ¼ .63 for HLA-A/B, HLA-C, and
HLA-DRB1, respectively.) (Figure 4B).
Comparison of One HR-MM and Two LR-MMs
To evaluate whether a donor with 1 HR-MM or a donor
with 2 LR-MMs should be preferred, we added patientswith 2
LR-MMs and thosewith 2 allele mismatches including at least
1 HR-MM to the dataset, and we compared the outcome of
HSCT from these donors with that of HSCT from a donor with
1 LR-MMas a reference in the combinedmid and late periods.
The presence of 2 LR-MMs was associated with a signiﬁ-
cantly higher incidence of grade III to IV acute GVHD (HR,1.44;
95% CI, 1.04 to 2.00; P¼ .030), but the impact of 1 HR-MMwas
not statistically signiﬁcant (HR, .94; 95% CI, .56 to 1.59; P¼ .83)
(Figure 5A). However, the impact of 2 LR-MMs was not asso-
ciated with inferior survival. The HR for survival of 1 HR-MM
and 2 LR-MMs were 1.05 (95% CI, .78 to 1.42; P ¼ .75) and 1.12
(95% CI, .90 to 1.39; P ¼ .33), respectively (Figure 5B).
On the other hand, the presence of 2 allele mismatches
including at least 1 HR-MMwas associatedwith an extremely
poor outcome; HR, 3.61 (95% CI, 1.96 to 6.66; P < .001) for
grade III to IV acute GVHD and HR, 2.02 (95% CI, 1.25 to 3.26;
P ¼ .0040) for overall survival. These results suggested that
the impact of HR-MMmay change according to the presence
or absence of an additional allele mismatch. In fact, there was
a statistically signiﬁcant interaction between the presence of
HR-MM and the presence of an additional allele mismatch
(P ¼ .020). The likelihood ratio test revealed that the prog-
nostic value of Fine and Gray’s proportional hazards model
for acute GVHD was signiﬁcantly improved by adding the
interaction term to the model (P ¼ .024).
DISCUSSION
In this study, we reevaluated the clinical impact of
HR-MMs in unrelated HSCT. We conﬁrmed that the presence
of HR-MMs was associated with a signiﬁcantly higher inci-
dence of grade III to IV acute GVHD and signiﬁcantly inferior
survival in the early transplantation time period. However,
in the mid and late periods, ie, after 2002, there was no
statistically signiﬁcant difference in overall survival or the
incidence of grade III to IV acute GVHD between patients
with HR-MMs and thosewith LR-MMs. Themethods used for
the statistical analyses were somewhat different than those
in a previous study, but this is not the major reason for the
different results, as the signiﬁcant impact of HR-MMs on
survival and acute GVHD was reproduced in the early time
period. Another possible explanation is a bias caused by the
availability of information about HR-MMs. After the publi-
cation of a paper that reported the importance of HR-MM,
physicians may have tended to intensify prophylaxis
against GVHD in unrelated HSCT with HR-MMs, and, thereby,
the impact of HR-MMs might have become less signiﬁcant.
However, this is not the case because the impact of HR-MMswas already not apparent in the mid time period, before the
paper was published. We also considered that the difference
in the underlying disease might have inﬂuenced the effect of
HR-MMs. The proportion of patients with CML decreased
from 30.7% in the early period to 10.4% and 3.6% in the mid
and late periods, respectively. Therefore, we analyzed the
impact of HR-MMs grouped according to the underlying
disease in the early period. The effect of HR-MMs on survival
was observed only in patients with CML (Figure 3A,B).
However, HR-MMs had an adverse effect on the incidence of
grade III to IV acute GVHD regardless of the underlying dis-
ease (Figure 3C,D). Therefore, the different effects of HR-MMs
on the incidence of grade III to IV acute GVHD among the
time periods could not be explained solely by the underlying
diseases. We could not clarify the reason for this different
effect, but the changes in the transplantation procedure, in-
cluding prophylaxis against GVHD, might have reduced the
clinical impact of HR-MM. In fact, the incidence of grade III to
IV acute GVHD decreased from 42.6%, 16.8%, and 14.5% in the
HR-MM, LR-MM, and MUD groups, respectively, in the early
time period to 17.6%, 17.7%, and 10.6% in the mid or late
period. Improved survival in patients who developed severe
acute GVHD might also reduce the effect of HR-MMS on
survival. The 1-year survival in patients who developed
grade III to IV acute GVHD improved from 32.1% in the early
period to 44.4% in the mid and late time periods. This change
may have resulted from the progress in supportive care,
including strategies against fungal or viral infections.
Another important ﬁnding is that the impact of HR-MM
was signiﬁcantly enhanced by the presence of an additional
allele mismatch in the mid and late time periods. This fact
may be explained by a hypothesis that the HR-MM biologi-
cally increases the graft-versus-host (GVH) reaction, but the
recent improvement in GVHD prophylaxis has masked its
effect, if HR-MM exists as a single allele mismatch, whereas
the adverse impact of HR-MM is not suppressed even by
recent methods of GVHD prophylaxis when an additional
allele mismatch is present. Based on these ﬁndings, inter-
action terms should be incorporated into the statistical
model when the impact of HR-MMs is analyzed in datasets
that include HSCT with multiple allele mismatches.
A major limitation of this study is the small number of
patients with HR-MMs, especially in the late time period. We
cannot deny the possibility that an important effect of
HR-MMs might be overlooked because of the poor statistical
power. The lack of a signiﬁcant difference in the incidence of
grade III to IV acute GVHD between unrelated HSCT with
HR-MMs at the HLA-A/B locus and HSCT with LR-MM should
be interpreted with caution, because of the small number of
patients. Furthermore, it was impossible to evaluate the
effect of each mismatch combination, as the number of
patients with each mismatch combination was most often
fewer than 10. HR-MMs associated with at least a 20% inci-
dence of grade III to IV acute GVHD in the mid and late
periods included A*0206-A*0201 (4 of 14), A*0206-A*0207
(3 of 4), B*1501-B*1507 (1 of 1), C*0801-C*0303 (4 of 15), and
C*1402-C*0304 (1 of 5), but the number of patients in each
pair was too small to draw any deﬁnitive conclusions.
When we consider the impact of HR-MMs, especially at
the HLA-C locus, we should also consider the effect of a killer
immunoglobulin-like receptor ligand (KIR) mismatch [13,14].
Among the 50 patients with HR-MMs at the HLA-C locus in
the mid and late periods, 20 had a KIR mismatch in the GVH
direction, whereas 30 did not. The incidence of grade III to IV
acute GVHD was 5% and 16.7%, respectively, but this
Y. Kanda et al. / Biol Blood Marrow Transplant 20 (2014) 526e535 535difference was not statistically signiﬁcant (P ¼ .24). The
incidence of grade III to IV acute GVHD in the 21 patients who
had LR-MMs and a KIR mismatch in the GVH direction was
15.0%. We could not conclude that a KIR mismatch had an
impact in this study because of the small number of patients
with a KIR mismatch in the GVH direction.
We should note that the results of the current study are
applicable to patients who receive bone marrow graft after a
myeloablative conditioning regimen. The impact of HR-MMs
may change according to the stem cell source or the condi-
tioning regimen. Therefore, further analyses are required
to evaluate the impact of HR-MMs in peripheral blood
stem cell transplantation and reduced-intensity conditioning
transplantation.
In conclusion, this retrospective study revealed that the
clinical impact of HR-MMs became less signiﬁcant after
2002. Although HR-MMs may have a biological impact, their
effect may be controlled by recent methods for GVHD pro-
phylaxis when they exist as a single allele mismatch. It may
still be prudent to avoid a donor with HR-MMs, especially at
the HLA-A or -B locus, if a donor with the other mismatch
combination is available. However, in the absence of MUD or
an unrelated donor with a LR-MM, a donor with a single HR-
MM could be a viable option for unrelated HSCT, and it is
preferred over a donor with 2 LR-MMs. In addition, we
should be aware that the clinical impact of risk factors may
change over time periods, and therefore, we should repeat-
edly conﬁrm the validity of risk factors.ACKNOWLEDGMENTS
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